Objective: To determine the prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency in the population tested, and to evaluate the prevalence of neonatal jaundice in newborns with G6PD deficiency. Methods: Cord blood of all babies born between October 1996 and October 1998 at the Royal Commission Medical Center in Yanbu, Saudi Arabia, was screened for G6PD deficiency by fluorescent spot test. The results of screening of cord blood samples were reported to the physician in charge, and also placed on the files of the babies and their mothers. These babies were observed for 72 h and discharged if no jaundice developed. Results: During this two-year period, 2505 neonatal cord blood samples from 1278 boys and 1227 girls were screened for G6PD. There were 50 positive results for G6PD deficiency (39 boys and 11 girls), and the prevalence was estimated to be around 2%. The sex-specific prevalence for boys was 3.05%, and for girls 0.9%. Male to female ratio was 3:1. Neonatal jaundice developed in six (12%) babies, five male and one female. All were treated with phototherapy and discharged within one week of birth. Conclusion: The prevalence of G6PD is relatively high in Yanbu. Routine neonatal screening in areas with a high prevalence of G6PD in Saudi Arabia is justifiable.
INTRODUCTION
G lucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common clinically significant red cell enzymopathy in humans, affecting around 400 million people worldwide. 1 Since the discovery of G6PD deficiency in 1956, at least 400 abnormal variants with different biochemical characteristics and about 100 diverse mutations have been identified. 2 In most cases, the phenotypic expression is a marked decrease in erythrocyte G6PD activity. The main clinical expression is a haemolytic anaemia, which can be acute or chronic. During the neonatal period, the disease may manifest as neonatal jaundice. The inheritance pattern in G6PD deficiency is X linked. Therefore, hemizygous males suffer from the effects of deficiency. Girls who are either homozygous or who are phenotypically deficient heterozygous (due to Lyonization) can demonstrate the manifestations of the disease. Genotypically heterozygous females are generally asymptomatic. However, homozygous females showing clinical manifestations are also encountered. 3 Neonatal jaundice with pathological hyperbilirubinaemia develops more frequently in cases of G6PD deficiency. 4, 5 Infants with the severe variant of G6PD deficiency may develop hyperbilirubinaemia sufficiently severe to cause kernicterus and death. 4, 5 During a previous cord blood screening programme, two studies were conducted in Riyadh and one Eastern province (Qatif and Al Hasa). In the Riyadh studies 2% and 3.8% of neonates were found to be G6PD-deficient, and in Qatif and Al Hasa, 30.6% and 14.7%. [5] [6] [7] Early diagnosis, education and epidemiological surveillance have proved to be the cornerstones in the prevention of the haemolytic disease. 2 The early characterization of G6PD activity provides an aetiological diagnosis for neonatal jaundice, as well as the opportunity to give the newborn's family information concerning haemolytic crisis prevention.
Therefore they should be taken into account in national health programmes, especially in countries with high prevalence rates. 8 The objective of our study was to determine the incidence of G6PD deficiency in the population tested, and to evaluate the prevalence of neonatal jaundice in newborns with G6PD deficiency.
MATERIALS AND METHODS
Cord blood samples from all babies born to Saudi mothers in the period from October 1996 to October 1998 were collected at the Royal Commission Medical Center in Yanbu city, in the western province of Saudi Arabia. The hospital is considered the only referral centre for the area. The practice at this centre is to discharge newborn infants with their mothers about 24 h after birth. Those readmitted for jaundice are admitted to the nursery isolation unit if less than 29 days old, and to the paediatric ward if older. The usual work-up for neonatal jaundice in this centre includes a complete blood count, blood smear for red cell morphology, blood groups of mother and infant, Coombs' test, and total serum bilirubin.
The samples collected in ethylenediamine tetraaceticacid (EDTA) anticoagulated tubes were screened for G6PD deficiency using fluorescent spot test (Boehringer Mannheim GmGH, West Germany). 9 Fluorescence is produced due to reduction of NADP to NADPH. This reaction is coupled with oxidation of glucose-6-phosphate to 6-phosphogluconate and catalysed by G6PD. Specimens with G6PD activity of less than 20% of normal do not fluoresce, as the small amount of NADPH formed is re-oxidized by the glutathione present in the reagents. The reports of screening of cord blood samples were sent to the physician in charge, and also placed on the files of the babies and their mothers. The practice in this centre is to initiate phototherapy for 
is undertaken at >20 mg/dL. Lower values are used for preterm. The samples were collected during working days and were tested for G6PD immediately. Data obtained for each infant included the gestational age, sex, nationality, weight, and the age at onset of jaundice.
Those babies with a positive G6PD test were observed for 72 h and discharged if no jaundice developed. The type of treatment and the length of stay in the hospital were recorded. Parents were informed if the result was positive for risk factors of haemolysis and precaution measurements. The hospital administration and the families co-operated with the protocol and understood the reason for keeping babies with positive G6PD deficiency test results in the hospital and the complication of jaundice if not treated.
RESULTS
During the two-year period of the study, a total of 2922 babies were born in our centre. We collected 2505 (86%) neonatal cord blood samples, 1278 from boys and 1227 from girls, and screened for G6PD. Among our sample group, 97% were from full-term neonates. There were 50 neonates positive for G6PD deficiency (39 boys and 11 girls) and the prevalence was estimated to be around 2%, the sex-specific prevalence for boys was 3.05% and for girls was 0.9%. Male to female ratio was 3:1. Neonatal jaundice developed in six G6PD-deficient babies (12%) from the second day onward: five boys and one girl. Three of the six babies weighed between 3000 and 3500 g, two weighed 2600-3000 g, and one baby weighed 2500 g. Serum bilirubin levels among these babies ranged from 10 to 19 mg/dL, with a mean of 15.5 mg/dL. Haemoglobin levels ranged from 14 to 19 g/dL with a mean of 15.9 g/dL, and mean reticulocyte counts were 3.6%. All six babies were treated with phototherapy and five were discharged within seven days of birth. One preterm baby was discharged on day eight. The mean duration of phototherapy was 2.7 days.
DISCUSSION
Several variants of G6PD were encountered in different regions of Saudi Arabia during extensive screening programmes. As Saudi Arabia is a large country, with approximately 16.5 million people living over an area of 2,149,690 km 2 , the prevalence in each region is not available. Different groups of researchers have evaluated the scope of G6PD deficiency among Saudi populations in different regions of the country. [5] [6] [7] [10] [11] [12] We reported in this neonatal study the prevalence of G6PD deficiency in Yanbu, in the west region of Saudi Arabia. This prevalence was estimated to be around 2%, which is similar to the 2% prevalence in Saudi Arabia reprted by Niazi et al., 5 but lower than the studies by al-Nuaim et al. in the Riyadh area, 6 and Zaki et al. in the Qatif and Al Hasa area. 7 Saudi neonates were found to be severely G6PD-deficient during a cord blood screening programme conducted from April to December 1992. 5 The prevalence of G6PD in other countries worldwide ranges from 0.09% in Italy 13 to 2.1% in Iran. 14 In an X-linked recessive disorder, the frequency of affected males is expected to be equal to the number of heterozygote females, but our screening method failed to produce this result. The sensitivity of our screening method might be not sufficient to detect all heterozygote females. This also might be explained by the fact that G6PD has different genetic types in Saudi Arabia. 12 Since heterozygote females might develop the symptoms of G6PD deficiency later, these results suggest that G6PD neonatal screening may not be helpful in preventing disease in women.
The link between different types of G6PD and neonatal jaundice is beyond doubt. Neonatal jaundice is the most common clinical manifestation of G6PD deficiency. It has been reported that one-third of children with G6PD deficiency develop neonatal jaundice. 3, 4 In the design of our study, 12% of G6PD patients developed neonatal jaundice, all of them treated with phototherapy, while Tanphaichitr et al. 15 reported that 49% of G6PD patients developed neonatal jaundice, of which 28.82% were physiological and 20% were pathological. Different subtypes of the disease could explain this with different presentations in different geographical locations worldwide. 3, 12 Calculating the sensitivity and specificity of this screening method is out of the scope of this study, but based on previous reports the neonatal cord blood G6PD deficiency screening had acceptable sensitivity (85.7%) and high specificity (98.1%). 16 The early characterization of G6PD activity provides an aetiological diagnosis for neonatal jaundice, as well as the opportunity to give the newborn's family information concerning haemolytic crisis prevention. Given the relatively high prevalence of G6PD, we think it is justifiable to conduct routine neonatal screening in areas with high prevalence in Saudi Arabia.
